Richardet 1993.

Methods	Randomised clinical trial with a cross‐over design Country: France Intention‐to‐treat analysis: not mentioned Sample size calculation: not reported
Participants	Demographic characteristics No information Inclusion criteria and degree of severity Non‐infected people with histologically confirmed alcoholic hepatitis. All participants had severe hepatic failure (prothrombin time < 50%, or bilirubin > 5.6 mg/dL, or encephalopathy) Randomisation procedure Not mentioned Number of participants randomised: 23 Glucocorticosteroid group: n = 12 Control group: n = 11
Interventions	Prednisolone group: prednisolone 40 mg daily Control group: placebo 40 mg daily Duration of treatment: Prednisolone group: 1 week of treatment followed by 1 week of no treatment Control group: 1 week of no treatment followed by 1 week of treatment After that, both groups received glucocorticosteroids for 3 weeks. Duration of follow‐up: at discharge from hospital (3 months)
Outcomes	Mortality Liver biochemistry
Notes	Letter sent to study authors in 2006. No answer received. Only published as abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Unclear risk	No information